Navigation Links
Quebec City researchers pave the way for novel treatment of pulmonary hypertension
Date:10/23/2010

Montreal - A Heart and Stroke Foundation researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.

"We have discovered an early warning system in a protein called PIM-1," Dr. Sbastien Bonnet told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Dr. Bonnet has established that the PIM-1 cells can be used as markers of pulmonary hypertension.

"Blood samples were taken from patients to measure PIM-1 expression in the blood," says Dr. Bonnet, who is a professor at Laval University and a researcher at Centre hospitalier universitaire de Qubec. "We were surprised to find that the greater the PIM-1 levels, the more severe the pulmonary hypertension in the patient."

He says this opens the doors to using regular blood tests to look at PIM-1 levels. "If there is a slight increase in PIM-1, we will know that something is going on." This is important since the condition is under-diagnosed and often not discovered until it is in a late stage. Without earlier treatment it has a very poor prognosis. The condition has traditionally been diagnosed by a six minute walking test.

PIM-1 also offers the opportunity to move beyond the diagnosis of pulmonary hypertension to treatment. By blocking the PIM-1 protein, researchers were able to reverse the condition.

"This is a remarkable finding," says Dr. Bonnet. "We have found that using gene therapy to inhibit the inappropriate activation of this protein is a novel and effective therapy that can reverse the disease altogether."

Before this discovery there has been no agent to reverse the disease. Current drug treatments can improve quality of life but to this date there has been nothing that can cure the disease.

"Pulmonary hypertension is a rare but life-threatening condition," says Heart and Stroke Foundation spokesperson Dr. Beth Abramson. "These are often very sick individuals. By the time a patient gets to a doctor, the disease is usually well established." Individuals at increased risk of developing pulmonary hypertension include those with a family history and people with a history of blood clots in the lungs (pulmonary embolism).

She recommends that patients pay particular attention to any symptoms like shortness of breath or extreme tiredness. "There are treatments that can help patients live longer, healthier lives."

Pulmonary hypertension is abnormally high blood pressure in the pulmonary arteries, the arteries which carry blood from the heart to the lungs. The condition makes it more difficult for blood to flow to the lungs, causing shortness of breath, fatigue, and swelling of the feet and ankles. It can make everyday tasks almost impossible.

The number of Canadians with pulmonary hypertension is difficult to estimate, because it is under-diagnosed and the early symptoms are common to other conditions such as asthma and general fatigue. In addition, few studies have been conducted.


'/>"/>

Contact: Jane-Diane Fraser
jfraser@hsf.ca
613-569-4361 x273
Heart and Stroke Foundation of Canada
Source:Eurekalert

Related medicine news :

1. Mount Sinai researchers discover origin of immune cells in the brain
2. UC San Diego researchers identify factor boosting leukemias aggressiveness
3. UCI stem cell researchers to receive $9.35 million in state funding
4. Researchers find better method to help mothers cope with childs cancer and related stress
5. Researchers advocate for more education and attention regarding rare breast cancer
6. Mount Sinai researchers discover why cocaine is so addictive
7. Temperature rhythms keep body clocks in sync, UT Southwestern researchers find
8. Need a study break to refresh? Maybe not, say Stanford researchers
9. Researchers reach consensus on use of deep brain stimulation to treat Parkinsons
10. AACR to honor leading researchers at breast cancer symposium
11. Medical researchers break down costs to care for heart failure patients at the end of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) ... Food & Beverage and Dietary Supplement market segments across ... and USA geographies east of the Rocky Mountains since 2012. Consistent performance ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... community enrichment program serving the greater Venice, FL area, has initiated a fundraiser ... in a car accident just four days after Christmas. To support this beautiful ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... 8, 2016  Dynatronics Corporation (NASDAQ: DYNT ... devices and rehabilitation equipment for the physical therapy, ... Broncos, football team for winning the 2016 World ... Chairman and Chief Executive Officer.  "The Broncos have ... forward to enhancing their athletic achievements with our ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
Breaking Medicine Technology: